Daniel M. Geynisman

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 451 citations

Medicine, Oncology, Surgery +16

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend et al. · The Lancet Oncology · 2021 · 412 citations · Full text

Medicine, Oncology, Pharmacology +12

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Nieves Martínez Chanzá, Wanling Xie, Mehmet Asım Bilen et al. · The Lancet Oncology · 2019 · 175 citations

Medicine, Oncology, Pharmacology +11

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2023 · 175 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011

Ya‐Chen Tina Shih, Fabrice Smieliauskas, Daniel M. Geynisman et al. · Journal of Clinical Oncology · 2015 · 159 citations · Full text

Public Affairs, Oncology, Pharmacoeconomics +17